Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Safety and efficacy of teclist...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis

Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis

Bibliographic Details
Main Authors: Rajshekhar Chakraborty, Divaya Bhutani, Mathew S. Maurer, Meera Mohan, Suzanne Lentzsch, Anita D’Souza
Format: Article
Language:English
Published: Nature Publishing Group 2023-11-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-023-00950-3
  • Holdings
  • Description
  • Similar Items
  • Staff View
Description
ISSN:2044-5385

Similar Items

  • PB2151: CLINICAL FEATURES AND OUTCOMES OF DIFFUSE PULMONARY LIGHT CHAIN AMYLOIDOSIS: A RARE PRESENTATION OF SYSTEMIC AL AMYLOIDOSIS
    by: Rajshekhar Chakraborty, et al.
    Published: (2023-08-01)
  • Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
    by: Meera Mohan, et al.
    Published: (2024-03-01)
  • Editorial: Advances in the understanding of pathogenesis, diagnosis, and therapy of light chain amyloidosis
    by: Divaya Bhutani, et al.
    Published: (2023-02-01)
  • Recent advances in understanding and treating immunoglobulin light chain amyloidosis [version 1; referees: 2 approved]
    by: Talha Badar, et al.
    Published: (2018-08-01)
  • Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type
    by: Eli Muchtar, et al.
    Published: (2016-09-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs